25(OH)-vitamin D and Its Association with Bone Density, Body Composition, Strength, Walking Speed, Physical Performance and Pain in Hospitalized Individuals with Neurological Disorders

The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters.
The NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed.
The study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers.
The findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.

开始日期2025-06-01

申办/合作机构-

NCT06964334

/ Not yet recruiting临床3期IIT

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection

Helicobacter pylori (H. pylori) is one of the most common chronic infections worldwide. The mode of transmission of H. pylori is through the fecal-oral or oral-oral routes.
Chronic gastritis has been linked to helicobacter pylori (H. pylori) infection. Peptic ulcer disease, gastric adenocarcinoma, and gastric lymphoma are all linked to this condition .
In Egypt, a high prevalence of H. pylori infections has been reported, ranging from 70% in the general population , 73% among school children , up to 88% in patients with chronic active HCV .
In 2007, the American College of Gastroenterology estimated that the cure rate for H. pylori infections was 70-85 percent with the use of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole .
children with H. pylori infection do not have severe digestive symptoms. pylori infection represents a key factor in the pathogenesis of duodenal ulcer and chronic gastritis in children. In addition, H. pylori infection has also been reported to have extra-digestive consequences .
A recent comprehensive evaluation found that sequential and conventional triple treatment had a cure rate of 84% .
The infected macrophage is unable to create enough 1,25-(OH)2D to control the synthesis of AMP cathelicidin when it is vitamin D deficient .
vitamin D has a powerful systemic antibacterial impact by enhancing the activity of monocytes and macrophages. Most illnesses seem to benefit from a vitamin D-rich condition .
Vitamin D-deficient subjects might be more prone to developing H. pylori infection .

开始日期2025-06-01

申办/合作机构

Assiut University

NCT06861062

/ Not yet recruitingN/AIIT

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Cardiovascular Disease in Patients with Type 2 Diabetes: a Randomized Double-Blind Controlled Trial

This study is a randomized, double-blind, placebo-controlled trial involving 8,000 individuals aged 40-79 with type 2 diabetes. The trial includes a 2-year intervention period followed by 3 years of follow-up. The primary objective is to investigate whether daily dietary supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the risk of major cardiovascular diseases, including myocardial infarction, stroke, treated or hospitalized heart failure, and cardiovascular deaths. The secondary objectives include evaluating the effects of vitamin D3 or yeast β-glucan supplementation on all-cause mortality, microvascular disease, cognitive function, and other outcomes.

开始日期2025-03-20

申办/合作机构

华中科技大学

100 项与维生素D3 相关的临床结果

登录后查看更多信息

100 项与维生素D3 相关的转化医学

登录后查看更多信息

100 项与维生素D3 相关的专利（医药）

登录后查看更多信息

24,457

项与维生素D3 相关的文献（医药）

2025-12-31·Artificial Cells Nanomedicine and Biotechnology

Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages

Article

作者: Ahmed, Rami ; Dube, Admire ; Khoza, Star ; Dlozi, Prince N.

Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis, remains a global health burden. Current antibiotic treatments are limited by adverse effects, poor adherence, and drug resistance, necessitating new therapeutic approaches. Recent studies highlight the role of vitamin D3 (VD3) in enhancing host immune responses against the mycobacterium via cathelicidin (an antimicrobial peptide) and autophagy activation. In this study, VD3-loaded poly-ƹ-caprolactone (PCL) nanoparticles (NPs) were synthesized to enhance cathelicidin expression in macrophages. NPs containing cholecalciferol, calcifediol, and calcitriol were synthesized using an emulsification solvent-evaporation technique. Average sizes of synthesized NPs ranged from 304.7 to 458.7 nm, with polydispersity index (PDI) and zeta potential (ZP) ranging from 0.103 to 0.257 and -17.3 to -7.47 mV, respectively. Encapsulation efficiencies were 9.68%, 10.99%, and 19.28% for cholecalciferol, calcifediol, and calcitriol, respectively. VD3-encapsulated NPs stimulated a dose-dependent increase in cathelicidin expression in THP-1 macrophages. Encapsulated calcifediol and calcitriol (100 ng/ml) induced the expression of 243.46 ng/ml ± 4.55 ng/ml and 396.67 ng/ml ± 25.24 ng/ml of cathelicidin, respectively, which was significantly higher than that induced by the free drugs. These findings suggest that NP encapsulation may offer a more efficient approach to using vitamin D3 for inducing cathelicidin expression as a host-directed treatment for TB.

2025-12-31·Environmental Pollutants and Bioavailability

Evaluating the influence of aquatic environmental hazard, polylactic acid microplastics, on Labeo rohita

作者: Al-Ghanim, Khalid A. ; Ali, Shafaqat ; Hussain, Syed Makhdoom ; Naeem, Adan ; Rashid, Eram ; Sarker, Pallab K.

This research sought to evaluate toxicity after intake of polylactic acid microplastics (PLA-MPs) on multiple parameters of Labeo rohita fingerlings, focusing on their growth, nutrient consumption, body composition, histopathol., hematol. and minerals status.Six test diets were formulated using sunflower meal (SFM) serving as the reference diet, incorporating different MPs concentrations: control (0%), 0.5%, 1%, 1.5%, 2% and 2.5% MPs.The formulated diets were administered to triplicate groups of 15 fish, with each fed at 5% weight (live wet) for 90 days duration.The outcomes revealed that the growth had significantly decreased in L. rohita fingerlings when exposed to PLA-MPs.Furthermore, the apparent nutrients digestibility reduced with the escalation in PLA-MPs levels.PLA-MP exposure led to substantial alterations in body composition, including enhanced body fat and reduced protein content.Furthermore, blood profile was also altered after the PLA-MPs exposure.Addnl., examination of gut histopathol. indicated an intensification in abnormalities in intestine at the 2.5% PLA-MPs concentrationThe diet having 2.5% MPs exhibited the min. body mineral compositionThis study suggests that exposure of PLA-MPs influenced the L. rohita health performance.

2025-12-01·IMMUNOLOGIC RESEARCH

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Article

作者: Naseri, Bahar ; Baradaran, Behzad ; Ghahramanipour, Zahra ; Sohrabi, Sepideh ; Karimzadeh, Hadi ; Mardi, Amirhossein ; Baghbani, Elham ; Masoumi, Javad

Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method. To differentiate monocytes from DCs, we utilized GM-CSF and IL-4 cytokines. Tolerogenic DCs were generated using vitamin D3 and dexamethasone. We added LPS and AVP to the culture medium on day 6 after incubation of DCs at 37 °C. Finally, we assessed the surface molecules by flow cytometry and used real-time PCR to evaluate the expression of genes related to the inhibitory immune checkpoints. Based on the obtained data, AVP increased the expression of CD11c (P ≤ 0.0001), HLA-DR (P ≤ 0.01), and CD86 (P ≤ 0.01) in AVP-mDCs. Also, the expression of all the immune checkpoint genes including CTLA-4 (P ≤ 0.001), BTLA (P ≤ 0.001), PDL-1 (P ≤ 0.05), B7H7 (P ≤ 0.001), LAG3 (P ≤ 0.01), and VISTA (P ≤ 0.001) in AVP-mDCs was increased in comparison to the control group. Vasopressin caused the generation of mature and tolerogenic DCs. Our data may help to consider AVP-mDCs to take part in autoimmune disease therapy, transplanted tissue rejection impedance, and allergies.

296

项与维生素D3 相关的新闻（医药）

2025-05-07

·梅斯医学

维生素D预防疾病，怎么补？补多少？新指南给出答案

在生活中，维生素 D 的重要性不言而喻。维生素 D不仅与肌肉骨骼健康密切相关，还与代谢、心血管、免疫等多种疾病存在潜在联系。然而，这种关联背后的确切因果关系尚未完全明确，导致临床实践中对于维生素 D 补充剂的使用存在诸多不确定性。2024年8月，美国内分泌学专家小组在《临床内分泌代谢杂志》（JCEM）在线发表了名为“维生素D预防疾病：内分泌学会临床实践指南”的指南，该指南中明确了从儿童到老年人、从健康人群到特定疾病风险群体预防疾病的维生素D需求量。本文结合指南的相关内容，为大家介绍补充维生素 D 预防疾病的相关知识。人体如何获得维生素 D ？人体获取维生素 D 主要通过皮肤合成、食物摄入以及补充剂这三种途径。皮肤合成是人体获取维生素 D 的主要方式。皮肤中的 7 - 脱氢胆固醇在阳光中的紫外线 B（UVB）照射下，会转化为维生素 D₃。一般每周让面部、手臂、腿部等部位在阳光下暴露 10 - 30 分钟，每周 2 - 3 次，就能满足人体对维生素 D 的部分需求。然而，过度日晒会增加皮肤癌风险，并且季节、时间、地理位置、肤色及防晒霜的使用等因素，都会影响皮肤合成维生素 D 的效果。正因皮肤合成存在诸多限制，所以食物摄入也成为获取维生素 D 的重要补充途径。虽然富含维生素 D 的天然食物不多，但仍有迹可循。深海鱼类，如三文鱼、金枪鱼、鳕鱼等，以及鱼卵、蛋黄、动物肝脏、奶制品都是维生素 D 的来源。此外，一些经过强化处理的食品，如部分品牌的牛奶、橙汁、谷物等，也能助力维生素 D 的补充。不过，食物中维生素 D 的含量有限，仅靠饮食往往难以满足人体全部需求。这时候，维生素 D 补充剂就成为了必要的获取方式。在日照不足、饮食摄入不足或患有某些疾病导致维生素 D 吸收不良等特殊情况下，补充剂就派上了用场。常见的维生素 D 补充剂有维生素 D₂和维生素 D₃。为了确保剂量准确、服用安全，建议在医生或营养师的指导下使用补充剂，以此保障人体能获得充足且适量的维生素 D，维持身体的正常运转。不同人群该如何补充维生素D？新指南为临床医生提供了全面而细致的指导，涵盖了不同人群维生素 D 补充的适用性、剂量以及检测的必要性。● 在儿童和青少年（1 - 18 岁）中，指南建议进行维生素 D 经验性补充，以预防营养性佝偻病并可能降低呼吸道感染风险。尽管没有随机安慰剂对照试验（RCTs）专门针对维生素 D 对儿童预防营养性佝偻病的疗效，但间接证据支持其预防作用。对于呼吸道感染，系统回顾纳入的 12 个 RCTs 显示维生素 D 对降低呼吸道感染风险有一定影响，尽管结果存在异质性，但偏倚风险较低的试验未显示明显差异。维生素 D 的剂量在试验中差异较大，估计加权平均剂量约为 1200 IU（30 μg）/ 天。这一建议体现了在缺乏明确 RCTs 证据的情况下，基于现有证据和临床经验的合理推断。● 对于非妊娠成人（< 50 岁），指南建议不超过膳食参考摄入量（DRIs）进行维生素 D 补充。系统回顾发现 2 个 RCTs 显示维生素 D 对预防呼吸道感染无显著差异；4 个研究对骨密度的影响结果不一，但大多数试验未发现显著差异。因此，指南不建议常规进行 25(OH)D 检测，因为目前没有明确证据表明特定 25(OH)D 水平可提供结局特异性益处。这一建议强调了在健康人群中，常规补充超过推荐量的维生素 D 并无额外益处。● 在 50 - 74 岁成人中，指南同样建议不超过膳食参考摄入量进行补充。纳入的 13 个 RCTs 显示维生素 D 对任何骨折的相对风险（RR）为 0.97，对全因死亡率影响的 13 个 RCTs 显示 RR 为 1.07，对癌症的 15 个 RCTs 显示 RR 为 1.00，对心血管事件的 14 个 RCTs 显示 RR 为 1.00 等，多数结果未显示显著差异。因此，指南不建议常规 25(OH)D 检测。这一部分的结论延续了对健康成人补充维生素 D 的谨慎态度，强调在没有明确疾病风险的情况下，遵循推荐摄入量即可。● 对于 75 岁及以上成人，指南建议进行维生素 D 经验性补充，可能降低死亡风险。纳入的 25 个试验显示维生素 D 可能降低死亡率，相对风险为 0.96。这一建议基于维生素 D 对老年人整体健康可能带来的益处，尽管具体机制尚不明确，但考虑到老年人群体的健康风险较高，补充维生素 D 可能是一种成本效益较高的预防措施。● 在妊娠期女性中，指南建议经验性补充维生素 D，可能降低先兆子痫、宫内死亡率、早产、小于胎龄儿和新生儿死亡率等风险。纳入的 10 个 RCTs 显示维生素 D 对这些结局有一定影响，但多数结果的 95%CI 包含无效值。尽管证据强度有限，考虑到妊娠期女性和胎儿的健康风险，指南仍建议进行维生素 D 补充。同时，不建议常规进行 25(OH)D 检测，以避免不必要的医疗负担。● 对于糖尿病前期成人，指南建议在生活方式干预的基础上进行维生素 D 经验性补充，以降低糖尿病进展风险。11 个 RCTs 显示维生素 D 可能降低糖尿病发生风险，相对风险为 0.90。这一建议为糖尿病前期人群提供了一种辅助预防手段，强调维生素 D 补充应作为整体生活方式干预的一部分。最后，指南还对维生素 D 补充剂的使用形式和 25(OH)D 检测提出了建议。对于 50 岁及以上、需维生素 D 补充或治疗的非妊娠人群，建议每日低剂量维生素 D 而非间歇性高剂量，以确保更稳定的血药浓度和更好的依从性。同时，指南不建议对健康成年人、深色肤色成人、肥胖成人等进行常规 25(OH)D 筛选，因为目前缺乏支持性临床试验证据。参考资料Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JME, McCartney CR. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. doi: 10.1210/clinem/dgae290. Erratum in: J Clin Endocrinol Metab. 2025 Feb 18;110(3):e916. doi: 10.1210/clinem/dgae854. PMID: 38828931.来源｜梅斯医学综合整理编辑 | miaoskr点击下方“阅读原文”，下载梅斯医学APP吧！

2025-04-23

·PRNewswire

ProRx Pharma Continues to Expand Preventative Health Portfolio with Six New Products

Expanded Product Line Targets Growing Demand for Proactive Wellness Solutions in Clinics, Med Spas, 503A Pharmacies, and Telehealth Practices Across the United States WEST PALM BEACH, Fla. and EXTON, Pa., April 23, 2025 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced the addition of six new injectable products designed to support the rising demand for preventive care: Gonadorelin, Liraglutide, Vitamin D3, and Phenylephrine HCl as well as two Tri-Mix injection options. These high-quality standalone injectables are now available for bulk shipping to licensed medical facilities in 26 states and for direct-to-consumer shipping nationwide through ProRx's growing network of 503A pharmacies, clinics, med spas and telehealth providers. "Patients are taking charge of their health like never before," said Kurt Lunkwitz, chief operating officer at ProRx. "Physicians are following suit, integrating wellness therapies into their practices to meet the demand for more proactive, functional care. This trend is only going to continue. The continued expansion of our health and wellness line is a direct response—and a step toward making preventative health more accessible and streamlined." What's New: The Products Each of the six new offerings comes with its own National Drug Code (NDC) number and an extended Beyond Use Date (BUD), providing both flexibility and longer shelf life for providers: Gonadorelin ( 1 mg/mL, 6 mg / 6 mL vial ) A gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. Gonadorelin may promote testosterone production; may support fertility, libido, and hormonal balance. Liraglutide ( 0.75 mg, 1 mg, 2 mg, 3 mg [custom dosing] ) A powerful GLP-1 receptor agonist for weight and blood-sugar management. Liraglutide may aid in weight loss, appetite suppression, and blood-sugar control. Vitamin D3 ( 50,000 IU/mL, 5 mL vial ) A high-dose solution for those with critically low vitamin D levels. Vitamin D3 may support immune function, bone health, mood, and Vitamin D repletion. Tri-Mix #1 ( 30 mg / 1 mg / 10 mcg/mL, 5 mL vial ) The first of two strength offerings for erectile dysfunction (ED) therapy. Tri Mix #1 may improve erectile response through smooth muscle relaxation and blood flow. Tri-Mix #2 ( 30 mg / 2 mg / 20 mcg/mL, 5 mL vial ) A stronger ED therapy offering. Tri-Mix #2, may provide more ED support for patients needing increased vasodilation. Phenylephrine HCl ( 0.1% 2 mL vial) A critical safety solution for patients using Tri-Mix therapies. Phenylephrine HCl may reverse prolonged erection or priapism due to ED therapy. The introduction of these six new products comes on the heels of ProRx announcing its first four preventative-care offerings the first week of April: Sermorelin, NAD+, Glutathione and MIC/B6/B12. Exclusive Launch at A4M Conference ProRx is showcasing its full line of preventative-care products at the A4M 33rd Annual Spring Conference taking place April 24-26 in West Palm Beach, Florida. At Booth 527, attendees will get an exclusive first look at all 10 products in the new product line and be able to speak with ProRx's experts about the company's compliance and quality-assurance programs. About ProRx Pharma ProRx Pharma is an FDA-registered cGMP facility focused on providing essential compounded medications to meet the need for medications on the FDA drug shortage and bulks list with an emphasis on preventative health. The company produces products and formulations for medical institutions, physician offices, and 503A pharmacies, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages. For more information, visit SOURCE ProRx Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-04-20

·米内网

正大天晴大涨1320%，382个西药厉害了！18个品牌大卖超10亿，石药挺进TOP10集团

精彩内容米内网最新数据显示，2024年中国城市实体药店终端西药（化学药+生物药）的销售规模继续保持正增长，涨至1904.95亿元。382个西药品牌卖过亿，“销冠”易主，超10亿品牌共有18个；26个过亿品牌增长率超过100%，正大天晴3款注射剂涨势惊人；恒瑞医药等34个国产新药大爆发。跨国药企实力强劲，国内药企正大制药、石药集团成功挺进TOP10集团。图1：中国城市实体药店终端西药（化学药+生物药）的销售情况（亿元）在中国城市实体药店终端，西药的销售规模一直稳步增长，2024年再创新高峰，达1904.95亿元，增长率保持在5%左右。14个大类中有13个的销售额呈现正增长，其中抗肿瘤和免疫调节剂的市场份额占22.83%，销售额增长了20.31%；全身用激素类制剂(不含性激素和胰岛素)的市场份额占0.38%，销售额增长了22.87%；心脑血管系统药物的市场份额占12.12%，销售额增长了2.68%。唯一销售额下滑的大类是消化系统及代谢药，市场份额占22.52%，销售额下滑3%左右。18个品牌大卖超10亿，新“销冠”来了，“神药”陨落了据统计，2024年销售额超过1亿元的西药品牌有382个（同一产品名涉及同一集团多家生产企业的，暂不合并统计，下同），涉及14个大类（54个亚类）。从亚类来看，抗肿瘤药以80个过亿品牌断层领先，高血压用药占了27个，糖尿病用药占了22个，矿物质补充剂占了18个，免疫抑制剂和维生素类各占17个，咳嗽和感冒用药、抗炎药和抗风湿药、全身用抗病毒药、全身用抗细菌药、血脂调节剂均有10个及以上。表1：2024年销售额在8亿元以上的西药品牌2024年在中国城市实体药店终端，382个销售额超过1亿元的西药品牌合揽超过1170亿市场。超10亿品牌有18个，其中8个国产品牌（不含原研地产化）包括了澳诺(中国)制药的葡萄糖酸钙锌口服溶液、青岛双鲸药业的维生素D滴剂、翰森制药的甲磺酸阿美替尼片、白云山制药总厂的枸橼酸西地那非片、施慧达药业集团(吉林)的苯磺酸左氨氯地平片、宜昌东阳光长江药业的磷酸奥司他韦颗粒、康方药业的卡度尼利单抗注射液、华润紫竹药业的左炔诺孕酮片。图2：澳诺(中国)制药的葡萄糖酸钙锌口服溶液销售情况（单位：万元）澳诺(中国)制药的葡萄糖酸钙锌口服溶液用于治疗因缺钙、锌引起的多种疾病。在中国城市实体药店终端，该品牌在2021年涨至19.6亿元，2022年突破20亿元关口，2023年销售额首次下滑，2024年止跌回升0.06%，以19.97亿元的销售额成为了西药市场新的冠军品牌。图3：翰森制药的甲磺酸阿美替尼片销售情况（单位：万元）甲磺酸阿美替尼片是翰森制药在2020年获批的国产1类新药，是第三代EGFR-TKI。在中国城市实体药店终端，该品牌在2023年突破11亿元，2024年再有39.34%的增长，销售额涨至15.7亿元，创出新高。在抗肿瘤药（化+生）市场，翰森制药的甲磺酸阿美替尼片已成为最畅销的内服品牌。图4：宜昌东阳光长江药业的磷酸奥司他韦颗粒销售情况（单位：万元）“流感神药”奥司他韦在2024年受到了重创，宜昌东阳光长江药业的磷酸奥司他韦颗粒是该品种最畅销的品牌，2023年在中国城市实体药店终端的销售额超过24亿元，是近九年的峰值，2024年急降51.21%，销售额跌至12亿元，同时该品牌也是382个过亿品牌中降幅最大的品牌，一代“神药”跌落神坛。236个品牌飞速增长！正大天晴飙涨1320%，34个国产新药大爆发2024年销售额超过1亿元的西药品牌中236个品牌有正增长，涨幅在100%以上的品牌有26个，其中国产品牌占了18个，正大天晴南京顺欣制药的注射用曲妥珠单抗、江西杏林白马药业的复合维生素B片涨幅达4位数。表2：2024年销售额过亿且增长率在100%以上的西药品牌图5：正大天晴南京顺欣制药3款注射剂的销售情况（单位：万元）正大天晴南京顺欣制药的注射用曲妥珠单抗、利妥昔单抗注射液和贝伐珠单抗注射液均是2023年获批的生物药3.3类新药，3大品牌获批当年在中国城市实体药店终端的销售额分别为900万元、5000万元、1.1亿元水平。2024年公司的注射用曲妥珠单抗暴涨1320.40%，销售额达1.37亿元，公司的利妥昔单抗注射液大涨260.07%，销售额突破2亿元，公司的贝伐珠单抗注射液也飙涨了184.23%，销售额超过3.2亿元。图6：杭州中美华东制药的他克莫司胶囊销售情况（单位：万元）杭州中美华东制药的他克莫司胶囊用于预防肝脏或肾脏移植术后的移植物排斥反应，以及治疗肝脏或肾脏移植术后应用其他免疫抑制药物无法控制的移植物排斥反应。在中国城市实体药店终端，该品牌在2023年大涨了46.66%，销售额超过9000万元，2024年暴涨134.66%，销售额突破2亿元。图7：湖南九典制药的洛索洛芬钠凝胶贴膏销售情况（单位：万元）湖南九典制药的洛索洛芬钠凝胶贴膏用于骨关节炎、肌肉痛、外伤后的肿胀疼痛。在中国城市实体药店终端，该品牌在2018-2024年均保持三位数增速，2023年大涨158.54%，销售额超过9000万元，2024年再涨122.34%，销售额也突破2亿元。表3：2024年销售额过亿且正增长的国产新药43个国产新药2024年在中国城市实体药店终端销售额超过1亿元，其中34个有正增长。创新药龙头恒瑞医药有4款新药上榜，其中瑞维鲁胺片大涨193.79%、羟乙磺酸达尔西利片大涨86.49%、阿得贝利单抗注射液大涨76.41%。翰森制药3款新药上榜，其中甲磺酸阿美替尼片2024年的销售额超过15亿元、艾米替诺福韦片增长了140%。三生制药的重组人血小板生成素注射液和注射用伊尼妥单抗增长率分别为64.55%、38.55%。荣昌制药的注射用泰它西普增长164.00%、注射用维迪西妥单抗增长了27.14%。跨国药企称霸，正大制药、石药集团成功突围2024年在中国城市实体药店终端，382个销售额超过1亿元的西药品牌归属170多个集团（二级），跨国巨头诺华、强生、拜耳、阿斯利康、罗氏牢牢占据前五位，过亿品牌在12个及以上，国内药企正大制药以10个过亿品牌突围，石药集团以9个过亿品牌挺进TOP10集团。图8：2024年过亿品牌≥8个的集团正大制药10个过亿品牌合揽接近28亿元，最畅销的是正大天晴药业集团的盐酸安罗替尼胶囊，2024年销售额达6.4亿元，增长率为3.75%。此外还有7个品牌呈现正增长，其中正大天晴南京顺欣制药的贝伐珠单抗注射液、利妥昔单抗注射液、注射用曲妥珠单抗分别增长了184.23%、260.07%、1320.40%，正大天晴药业集团的泊马度胺胶囊、达沙替尼片分别增长了18.11%、6.03%，江苏正大清江制药的盐酸氨基葡萄糖片增长了83.71%，北京泰德制药的氟比洛芬凝胶贴膏增长了7.84%。石药集团9个过亿品牌合揽超过19亿元，最畅销的是石药中诺药业(石家庄)的阿莫西林胶囊，2024年销售额超过4.2亿元，增长率为2.25%。此外还有5个品牌呈现正增长，石药欧意药业的甲钴胺片、头孢克肟胶囊、奥美拉唑肠溶胶囊、盐酸多柔比星脂质体注射液分别增长了51.55%、21.94%、14.80%、23.16%，石药恩必普药业的丁苯酞软胶囊增长了4.16%。资料来源：米内网数据库注：米内网《中国城市实体药店终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

免疫疗法

100 项与维生素D3 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00188	维生素D3	A11CC05	DB00169

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
维生素D缺乏症	中国	江苏吴中医药集团有限公司	1987-01-01
甲状旁腺功能减退症	加拿大	-	1985-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期后骨质疏松	临床3期	韩国	Alvogen Korea Co., Ltd.	2011-12-01
慢性心力衰竭	临床3期	意大利	Abiogen Pharma SpA	2011-11-01
高钙血症	临床3期	丹麦	University of Aarhus	2008-05-01
原发性甲状旁腺功能亢进症	临床3期	丹麦	University of Aarhus	2008-05-01
克罗恩病	临床3期	丹麦	University of Aarhus	2005-09-01
下尿路感染性疾病	临床2期	中国	上海泽生科技开发股份有限公司	2021-05-08
骨质疏松症	临床2期	丹麦	University of Aarhus	2015-12-01
类风湿关节炎	临床2期	丹麦	University of Aarhus	2015-12-01
2型糖尿病	临床2期	丹麦	University of Aarhus	2008-12-01
肌肉减少症	临床1期	美国	Metabolic Technologies, Inc.	2008-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04428359 (Pubmed \| Health Sci Rep)	N/A	疣	61	Intralesional MMR Vaccine	窪鹹餘夢網願鏇襯糧顧(鏇繭醖壓鹽構壓顧淵鏇) = rare with MMR 壓簾簾淵製膚鏇鏇獵鬱 (簾網構蓋齋夢鹽鬱鹹膚 ) 更多	积极	2025-05-01
				Intralesional Vitamin D3
NCT01817166 (D-Lay MS, NEWS \| Pubmed) 人工标引	临床3期	多发性硬化症	316	cholecalciferol	餘獵製膚壓鬱廠鬱衊構(醖築糧簾鹹齋醖鑰顧築) = 淵窪製鹽積襯壓鹹顧網窪選衊繭積網繭鑰淵糧 (廠夢積鬱膚簾鹹鹹鹽願 ) 更多	积极	2025-03-11
				Placebo	餘獵製膚壓鬱廠鬱衊構(醖築糧簾鹹齋醖鑰顧築) = 壓構遞鏇蓋艱築鹹選獵窪選衊繭積網繭鑰淵糧 (廠夢積鬱膚簾鹹鹹鹽願 ) 更多
NCT02224144 (CTgov)	临床2期	代谢性骨病 \| 血管钙化 \| 终末期肾脏病 ... 更多	61	Calcitriol+Vitamin D3 (Vitamin D3 Plus Calcitriol)	築艱築艱製窪積膚構範(獵鹽獵鏇構繭鏇選積衊) = 廠鑰顧願鹹網鏇齋衊顧蓋蓋構鏇網製餘醖襯繭 (鹽顧醖蓋顧淵窪窪網製, 0.54) 更多	-	2025-03-07
				Placebo+Vitamin D3 (Vitamin D3 Plus Placebo)	築艱築艱製窪積膚構範(獵鹽獵鏇構繭鏇選積衊) = 獵鹹築遞鹽構築鏇鏇艱蓋蓋構鏇網製餘醖襯繭 (鹽顧醖蓋顧淵窪窪網製, 0.46) 更多
NCT01748448 (ViDMe, CTgov)	临床3期	皮肤黑色素瘤	436	Vitamin D (Vitamin D)	衊鬱蓋壓鏇網選鏇餘築 = 範鑰選網繭繭簾餘壓餘夢範願齋淵積簾糧蓋遞 (簾醖網鑰壓製蓋鏇繭願, 鬱壓餘壓鑰遞淵窪獵願 ~ 構築鬱範憲鹽構壓膚壓) 更多	-	2025-02-17
				Placebo: Oil (Placebo: Oil)	衊鬱蓋壓鏇網選鏇餘築 = 顧觸憲艱範膚網顧廠繭夢範願齋淵積簾糧蓋遞 (簾醖網鑰壓製蓋鏇繭願, 憲廠齋艱憲襯鬱糧襯範 ~ 製網製鹽廠築憲蓋鑰糧) 更多
NCT01443728 (CTgov)	临床2期	哮喘 \| 维生素D缺乏症 \| 急性胸部综合征 ... 更多	70	Experimental: Vitamin D3 100,000 IU (Vitamin D3 100,000 IU)	壓築廠鹹願鑰衊選齋夢(齋衊遞簾鬱鹽願衊製淵) = 獵鏇鏇顧鹹襯憲遞衊醖餘膚蓋糧獵構鏇醖製淵 (鹹淵遞醖築願膚膚積製, 0.35) 更多	-	2024-08-09
				Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU)	壓築廠鹹願鑰衊選齋夢(齋衊遞簾鬱鹽願衊製淵) = 顧膚鑰鹹壓鬱鹽網鑰齋餘膚蓋糧獵構鏇醖製淵 (鹹淵遞醖築願膚膚積製, 0.35) 更多
625-P (ADA2024)	N/A	2型糖尿病 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	願積顧願範壓襯鏇鏇醖(築顧齋襯窪構憲齋製願) = 遞鑰鏇廠願範網築夢壓糧醖積窪鹹繭夢醖鏇遞 (繭構淵網糧糧窪範獵範 ) 更多	积极	2024-06-14
				Vitamin D (Higher VD group)	願積顧願範壓襯鏇鏇醖(築顧齋襯窪構憲齋製願) = 膚獵膚艱壓膚鏇糧繭簾糧醖積窪鹹繭夢醖鏇遞 (繭構淵網糧糧窪範獵範 ) 更多
EULAR2024	N/A	纤维肌痛 Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	鬱蓋艱艱觸鏇蓋衊選齋(繭鬱艱壓艱鏇壓廠築築) = 憲製獵憲遞衊鬱鏇簾鑰膚願膚艱壓鑰淵蓋艱築 (鹽觸淵築艱齋製壓糧壓 )	积极	2024-06-05
				Vitamin D (Healthy individuals)	鬱蓋艱艱觸鏇蓋衊選齋(繭鬱艱壓艱鏇壓廠築築) = 鑰夢網積繭範糧憲築鹽膚願膚艱壓鑰淵蓋艱築 (鹽觸淵築艱齋製壓糧壓 )
EULAR2024	N/A	系统性红斑狼疮	-	Vitamin D (SLE Female Patients)	齋淵醖獵鹹夢蓋衊繭糧(衊鑰製觸鬱鑰蓋構範鑰) = 襯衊齋襯鏇襯積壓遞夢衊築鏇淵襯夢鬱衊觸憲 (膚網淵醖廠鹹鏇鹽餘憲 )	-	2024-06-05
				Vitamin D (Control Group)	齋淵醖獵鹹夢蓋衊繭糧(衊鑰製觸鬱鑰蓋構範鑰) = 壓繭遞顧醖網積醖鏇觸衊築鏇淵襯夢鬱衊觸憲 (膚網淵醖廠鹹鏇鹽餘憲 )
ENDO2024	N/A	原发性甲状旁腺功能亢进症 1,25(OH)2 vitamin D \| FGF23	-	Vitamin D (PHPT patients)	齋衊糧積網壓獵網廠築(夢獵遞鬱繭廠糧鹽衊窪) = 齋選醖簾鬱繭遞積獵構積觸簾醖鬱廠膚選鹽夢 (積網膚醖遞淵齋壓築積 ) 更多	-	2024-06-01
				Vitamin D (Healthy individuals (CTRL))	齋衊糧積網壓獵網廠築(夢獵遞鬱繭廠糧鹽衊窪) = 鹽齋廠願鬱構選齋獵壓積觸簾醖鬱廠膚選鹽夢 (積網膚醖遞淵齋壓築積 ) 更多
NCT01169259 (VITAL, ENDO2024)	临床3期	2型糖尿病	-	Vitamin D 2000 IU/d	獵築範範鏇遞獵糧憲餘(獵憲壓觸積簾範艱選衊) = 餘鏇廠餘齋夢築繭窪選淵淵衊衊願鹹糧膚選窪 (選齋壓鑰積遞範繭簾鑰 )	不佳	2024-06-01
				Vitamin D (Placebo)	獵築範範鏇遞獵糧憲餘(獵憲壓觸積簾範艱選衊) = 糧觸窪壓構鑰廠壓憲襯淵淵衊衊願鹹糧膚選窪 (選齋壓鑰積遞範繭簾鑰 )